Our Alzheimer’s Disease test offers a non-invasive and highly accurate method to detect early biomarkers of the disease, specifically targeting the p-Tau 217 protein，the only plasma biomarker identified by Alzheimer’s Association Workgroup as appropriate for diagnosis of amyloid pathology for Alzheimer’s Disease. With over 90% diagnostic accuracy, this blood-based test provides a groundbreaking alternative to invasive procedures like spinal taps. This test uses ultrasensitive Single Molecule Detection technology to identify amyloid plaques associated with memory loss, it can detect Aheimer’s Disease 5 to 10 years before early symptoms appear, helping to guide treatment options and offering critical insights into disease progression for both patients and caregivers.